Search

MannKind Corp

Aperta

SettoreSettore sanitario

3.75

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.73

Massimo

3.82

Metriche Chiave

By Trading Economics

Entrata

-2.4M

-19M

Vendite

19M

109M

P/E

Media del settore

140.5

56.597

EPS

-0.06

Margine di Profitto

-17.401

Dipendenti

591

EBITDA

10M

13M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+112.93% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

131M

1.3B

Apertura precedente

3.75

Chiusura precedente

3.75

Notizie sul Sentiment di mercato

By Acuity

72%

28%

301 / 339 Classifica in Healthcare

MannKind Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 19:46 UTC

News

MannKind Corp shares are lower today amid broader market trends and inflation data, marking a third consecutive session of declines.

10 set 2026, 22:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting notable gains since Thursday's close, though still below the 20-day moving average.

9 set 2026, 20:01 UTC

Social Media
News

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

8 set 2026, 20:07 UTC

News

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

4 set 2026, 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

3 set 2026, 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

1 set 2026, 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

31 ago 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

28 ago 2026, 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

27 ago 2026, 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

26 ago 2026, 20:56 UTC

MannKind Corp shares are higher in after-market trading, reflecting unusual activity. The stock is significantly above its 20-day moving average.

21 ago 2026, 19:41 UTC

MannKind Corp. shares are lower today, trading near the lower end of their one-month range while above the 20-day moving average.

20 ago 2026, 19:51 UTC

Correlated Moves

MNKD lower today amid declines in the biotechnology sector.

19 ago 2026, 23:02 UTC

Correlated Moves

MannKind Corp shares are lower in after-market hours, continuing a downward trend amid broader declines in the biotechnology sector.

18 ago 2026, 22:51 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by rising sovereign bond yields.

17 ago 2026, 19:46 UTC

News

HC Wainwright lowered Q3 2026 EPS estimates for MannKind Corp to -$0.10 but maintained a “Buy” rating. Shares are higher since Friday's close.

14 ago 2026, 19:56 UTC

MannKind Corp. shares are higher today, reversing a four-session decline despite a broader market influenced by a drop in U.S. retail sales.

13 ago 2026, 19:01 UTC

MannKind Corp's shares are lower Thursday, continuing a five-day decline amid mixed economic signals and no specific news identified to explain the drop.

12 ago 2026, 20:06 UTC

MannKind Corp shares are lower today, continuing a decline since Tuesday's close amid shifting U.S. Treasury yields and broader market uncertainties.

11 ago 2026, 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

10 ago 2026, 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

7 ago 2026, 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

6 ago 2026, 22:01 UTC

MannKind Corp shares are lower in after-market trading, reflecting broader market weakness and trading below their 20-day moving average. No specific news was identified.

5 ago 2026, 23:02 UTC

News

MannKind Corp shares declined after-hours following a second-quarter earnings miss, despite reporting revenues of $109.4 million and FDA approvals for new products.

4 ago 2026, 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3 ago 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 lug 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 lug 2026, 18:41 UTC

Event
News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 lug 2026, 19:47 UTC

News
Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 lug 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

Confronto tra pari

Modifica del prezzo

MannKind Corp Previsione

Obiettivo di Prezzo

By TipRanks

112.93% in crescita

Previsioni per 12 mesi

Media 7.985 USD  112.93%

Alto 13 USD

Basso 4.16 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MannKind Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

301 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat